Skip to main content
. 2013 Feb 21;9(2):e1002899. doi: 10.1371/journal.pcbi.1002899

Table 2. Novel resistance conferring mutations derived from the dataset (NNRTI).

Mutation DLV EFV ETR NVP Average Log FC
P9T 0.36 1.01 0.65 0.46 0.62
E79D 0.34 0.55 0.61 0.34 0.46
K101S 0.38 0.73 0.31 0.44 0.47
K102Y 0.72 0.53 0.47 0.77 0.62
S156A 0.8 1.2 0.76 0.67 0.86
M164L 0.26 0.89 0.51 0.62 0.57
T216M 0.97 1.47 0.01 0.84 0.82
Y232H 0.47 0.62 0.36 0.47 0.48
R307M 0.92 0.14 0.28 0.35 0.42
Average Susceptibility 0.58 0.79 0.44 0.55 -

The value in the different drug columns indicates the average Log FC in the presence of this mutation. While these mutations have been selected to confer some resistance to all NNRTIs, each drug still has a distinct profile. Efavirenz is the most sensitive (average Log FC 0.79) and Etravirine the least (average Log FC 0.44) with Nevirapine (average Log FC 0.55) and Delavirdine (average Log FC 0.58) in between.